TOP1288

DRUG3 trials

Sponsors

Topivert Pharma Ltd

Conditions

Ulcerative Colitis

Phase 1

Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects

CompletedNCT02463045

Topivert Pharma LtdUlcerative Colitis

Start: 2015-05-31End: 2016-07-31Updated: 2017-05-23

Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects

CompletedNCT03071081

Topivert Pharma LtdUlcerative Colitis

Start: 2017-02-08End: 2017-06-02Updated: 2018-09-20

Phase 2

Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis

CompletedNCT02888379

Topivert Pharma LtdUlcerative Colitis

Start: 2016-09-30End: 2017-06-28Updated: 2017-07-07